TWI799923B - Use of thioimidazolidinone drugs in the treatment of covid-19 disease - Google Patents
Use of thioimidazolidinone drugs in the treatment of covid-19 disease Download PDFInfo
- Publication number
- TWI799923B TWI799923B TW110127077A TW110127077A TWI799923B TW I799923 B TWI799923 B TW I799923B TW 110127077 A TW110127077 A TW 110127077A TW 110127077 A TW110127077 A TW 110127077A TW I799923 B TWI799923 B TW I799923B
- Authority
- TW
- Taiwan
- Prior art keywords
- thioimidazolidinone
- covid
- drugs
- disease
- treatment
- Prior art date
Links
- RBLZMQODVSLEHV-UHFFFAOYSA-N 1-sulfanylimidazolidin-2-one Chemical compound SN1CCNC1=O RBLZMQODVSLEHV-UHFFFAOYSA-N 0.000 title 1
- 208000025721 COVID-19 Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011640468 | 2020-12-31 | ||
| CN202011640468.9 | 2020-12-31 | ||
| CN202110657053.0 | 2021-06-11 | ||
| CN202110657053.0A CN113143924B (en) | 2020-12-31 | 2021-06-11 | Application of thioimidazolidinone medicament in treating COVID-19 diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202227065A TW202227065A (en) | 2022-07-16 |
| TWI799923B true TWI799923B (en) | 2023-04-21 |
Family
ID=76875845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110127077A TWI799923B (en) | 2020-12-31 | 2021-07-21 | Use of thioimidazolidinone drugs in the treatment of covid-19 disease |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113143924B (en) |
| TW (1) | TWI799923B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022141328A1 (en) * | 2020-12-31 | 2022-07-07 | 苏州开拓药业股份有限公司 | Use of thioimidazolidinone drug in treating covid-19-related diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| CN106810542A (en) * | 2015-11-30 | 2017-06-09 | 苏州开拓药业有限公司 | A kind of crystal formation, salt form of thiocarbamoyl imidazole alkanone compound and preparation method thereof |
-
2021
- 2021-06-11 CN CN202110657053.0A patent/CN113143924B/en active Active
- 2021-07-21 TW TW110127077A patent/TWI799923B/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| CN106810542A (en) * | 2015-11-30 | 2017-06-09 | 苏州开拓药业有限公司 | A kind of crystal formation, salt form of thiocarbamoyl imidazole alkanone compound and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803. |
| 期刊 , S WU, et al., "Suppression of androgen receptor (AR)-ACE2/TMPRSS2 axis by AR antagonists may be therapeutically beneficial for male COVID-2019 patients", SSRN, SSRN, Posted: 18 Jun 2020, http://dx.doi.org/10.2139/ssrn.3580526.;期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113143924B (en) | 2023-04-14 |
| CN113143924A (en) | 2021-07-23 |
| TW202227065A (en) | 2022-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314347A (en) | Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine | |
| IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
| EP4215208A4 (en) | Pharmaceutical combination and use thereof | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| EP3969125A4 (en) | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases | |
| EP3915985A4 (en) | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | |
| EP4003355A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP4129283A4 (en) | Pharmaceutical combination and use thereof | |
| CA3264923A1 (en) | Composition for use in the treatment of fabry disease | |
| TWI799923B (en) | Use of thioimidazolidinone drugs in the treatment of covid-19 disease | |
| EP3644753A4 (en) | Methods for maintaining and improving kidney function in patients with kidney disease and on standard of care therapy | |
| EP4140480A4 (en) | Drug combination and use thereof | |
| EP4193995A4 (en) | Use of btk inhibitors in the treatment of diseases | |
| EP4234035A3 (en) | A pharmaceutical combination for the treatment of a cancer | |
| ITMI20021866A1 (en) | PHARMACEUTICAL PREPARATION IN COLLOIDAL FORM USEFUL IN THE TREATMENT OF SKIN DISEASES. | |
| EP4003987A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP4017496A4 (en) | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases | |
| PL3937948T3 (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
| EP3844168A4 (en) | Combination drug formulations for treating patients with cardiovascular disease and associated conditions | |
| EP4121035A4 (en) | Use of bucillamine in the treatment of infectious diseases | |
| EP4342492A4 (en) | Pharmaceutical combination and use thereof | |
| EP4129282A4 (en) | Pharmaceutical combination and use thereof | |
| EP4003997A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| HK40096009A (en) | Use of medicament in treatment of tumor disease |